Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer

• Drug: capecitabine
  
  Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
• Drug: oxaliplatin
  
  Oxaliplatin is given 110mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
• Drug: sunitinib malate
  
  sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
  Other Name: Sutent
• Drug: cisplatin
  
  Cisplatin is given 80mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
• Drug: sunitinib malate
  
  sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.

• Experimental: A
  
  Interventions:
  

  • Drug: capecitabine
  • Drug: oxaliplatin
  • Drug: sunitinib malate
• Experimental: B
  
  Interventions:
  

  • Drug: capecitabine
  • Drug: cisplatin
  • Drug: sunitinib malate

Inclusion Criteria:

• confirmed diagnosis of stomach cancer
• advanced stomach cancer of stage IV
• adequate blood chemistry, blood counts and kidney function
• willing to participate to study requirements and sign an informed consent document

Exclusion Criteria:

• prior chemotherapy for the stomach cancer in its advanced stage
• excessive toxicities related to prior therapies
• pregnant or breastfeeding patients